{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:19:30Z","timestamp":1783171170507,"version":"3.54.6"},"reference-count":250,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000928","name":"The Welch Foundation","doi-asserted-by":"publisher","award":["AU-0042-20030616"],"award-info":[{"award-number":["AU-0042-20030616"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["hLife"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.hlife.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:56:56Z","timestamp":1777319816000},"page":"331-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering nasally delivered IgM antibodies for respiratory viral infections"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-6823","authenticated-orcid":false,"given":"Ashwin Kumar","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlife.2026.03.004_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the global Burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hlife.2026.03.004_bib2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/ageing\/afab015","article-title":"COVID-19 testing in English care homes and implications for staff and residents","volume":"50","author":"Micocci","year":"2021","journal-title":"Age Ageing"},{"key":"10.1016\/j.hlife.2026.03.004_bib3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.15585\/mmwr.mm7432a2","article-title":"Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices\u2014United States, 2025\u20132026 influenza season","volume":"74","author":"Grohskopf","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.hlife.2026.03.004_bib4","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib7","first-page":"233","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antib Ther"},{"key":"10.1016\/j.hlife.2026.03.004_bib8","first-page":"132","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","volume":"7","author":"Strohl","year":"2024","journal-title":"Antib Ther"},{"key":"10.1016\/j.hlife.2026.03.004_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.03.004_bib11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.hlife.2026.03.004_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41586-021-03673-2","article-title":"Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants","volume":"595","author":"Ku","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.03.004_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1939605","article-title":"The biophysical principles underpinning muco-trapping functions of antibodies","volume":"18","author":"Schaefer","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.hlife.2026.03.004_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2025.169104","article-title":"Defining the features of complement-active IgM","volume":"437","author":"Watson","year":"2025","journal-title":"J Mol Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib21","doi-asserted-by":"crossref","first-page":"11900","DOI":"10.1073\/pnas.1901841116","article-title":"Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b","volume":"116","author":"Sharp","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib16","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3390\/ijms22052284","article-title":"Role of polymeric immunoglobulin receptor in IgA and IgM transcytosis","volume":"22","author":"Wei","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib17","doi-asserted-by":"crossref","first-page":"F5","DOI":"10.1097\/QAD.0000000000001857","article-title":"Anti-HIV IgM protects against mucosal SHIV transmission","volume":"32","author":"Gong","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.hlife.2026.03.004_bib18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1164\/rccm.201804-0734OC","article-title":"Localization of secretory mucins MUC5AC and MUC5B in normal\/healthy human airways","volume":"199","author":"Okuda","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.hlife.2026.03.004_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.03.004_bib23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4049\/jimmunol.1102107","article-title":"Natural IgM in immune equilibrium and harnessing their therapeutic potential","volume":"188","author":"Kaveri","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0167-5699(89)90268-5","article-title":"CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire","volume":"10","author":"Casali","year":"1989","journal-title":"Immunol Today"},{"key":"10.1016\/j.hlife.2026.03.004_bib25","first-page":"167","article-title":"Structure and function of natural antibodies","volume":"210","author":"Casali","year":"1996","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fimmu.2012.00066","article-title":"Protective roles of natural IgM antibodies","volume":"3","author":"Gr\u00f6nwall","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0167-5699(94)90313-1","article-title":"IgM hexamers?","volume":"15","author":"Brewer","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.hlife.2026.03.004_bib28","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.4049\/jimmunol.154.10.5265","article-title":"Assembly of IgM. Role of disulfide bonding and noncovalent interactions","volume":"154","author":"Wiersma","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.aaz5425","article-title":"Structural insights into immunoglobulin M","volume":"367","author":"Li","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib30","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1038\/s41467-022-34090-2","article-title":"Cryomicroscopy reveals the structural basis for a flexible Hinge motion in the immunoglobulin M pentamer","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib71","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.0105-2896.2005.00278.x","article-title":"The polymeric immunoglobulin receptor: Bridging innate and adaptive immune responses at mucosal surfaces","volume":"206","author":"Kaetzel","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.hlife.2026.03.004_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/antib9040070","article-title":"Fc Engineering strategies to advance IgA antibodies as therapeutic agents","volume":"9","author":"van Tetering","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.hlife.2026.03.004_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006948","article-title":"IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models","volume":"11","author":"Stip","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hlife.2026.03.004_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s44318-024-00317-9","article-title":"How J-chain ensures the assembly of immunoglobulin IgM pentamers","volume":"44","author":"Giannone","year":"2025","journal-title":"EMBO J"},{"key":"10.1016\/j.hlife.2026.03.004_bib32","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1016\/S0021-9258(19)37143-1","article-title":"Direct evidence that J chain regulates the polymeric structure of IgM in antibody-secreting B cells","volume":"267","author":"Randall","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hlife.2026.03.004_bib33","doi-asserted-by":"crossref","first-page":"10183","DOI":"10.1073\/pnas.1300547110","article-title":"High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation","volume":"110","author":"M\u00fcller","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108790","article-title":"Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2","volume":"34","author":"Gasser","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.hlife.2026.03.004_bib35","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1128\/CVI.00374-14","article-title":"Influenza virus-specific neutralizing IgM antibodies persist for a lifetime","volume":"21","author":"Skountzou","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nri2849","article-title":"The importance of natural IgM: Scavenger, protector and regulator","volume":"10","author":"Ehrenstein","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-024-02043-4","article-title":"Mucosal immune response in biology, disease prevention and treatment","volume":"10","author":"Zhou","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.hlife.2026.03.004_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fimmu.2013.00185","article-title":"Multi-faceted functions of secretory IgA at mucosal surfaces","volume":"4","author":"Corth\u00e9sy","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/mi.2011.41","article-title":"Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut","volume":"4","author":"Mantis","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib41","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41590-025-02156-0","article-title":"Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice","volume":"26","author":"Kwon","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib42","doi-asserted-by":"crossref","first-page":"RP88387","DOI":"10.7554\/eLife.88387","article-title":"Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein","volume":"12","author":"Waki","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.hlife.2026.03.004_bib43","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41590-024-01951-5","article-title":"Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates","volume":"25","author":"Gagne","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hlife.2025.05.001","article-title":"Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings","volume":"3","author":"Wang","year":"2025","journal-title":"hLife"},{"key":"10.1016\/j.hlife.2026.03.004_bib45","doi-asserted-by":"crossref","first-page":"eabj5129","DOI":"10.1126\/sciimmunol.abj5129","article-title":"Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA","volume":"6","author":"Oh","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/1348-0421.12775","article-title":"Human immune responses elicited by an intranasal inactivated H5 influenza vaccine","volume":"64","author":"Ainai","year":"2020","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib47","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/21645515.2018.1438791","article-title":"IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration","volume":"14","author":"Terauchi","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.hlife.2026.03.004_bib48","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1016\/j.vaccine.2017.07.093","article-title":"Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus","volume":"35","author":"Suzuki","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.hlife.2026.03.004_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib50","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.hlife.2024.05.004","article-title":"Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion","volume":"2","author":"Chen","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.hlife.2026.03.004_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antib9040053","article-title":"Structure, function, and therapeutic use of IgM antibodies","volume":"9","author":"Keyt","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.hlife.2026.03.004_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2031483","article-title":"Therapeutic antibodies for COVID-19: Is a new age of IgM, IgA and bispecific antibodies coming?","volume":"14","author":"Zhang","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.hlife.2026.03.004_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085582","article-title":"Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: Increased potential of IgA for heterosubtypic immunity","volume":"9","author":"Muramatsu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.hlife.2026.03.004_bib55","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ymthe.2025.02.041","article-title":"Nasal delivery of secretory IgA confers enhanced neutralizing activity against Omicron variants compared to its IgG counterpart","volume":"33","author":"Zhang","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlife.2026.03.004_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007427","article-title":"IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody","volume":"15","author":"Saito","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.hlife.2026.03.004_bib57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00018-015-2074-0","article-title":"Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles","volume":"73","author":"Virdi","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib59","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1080\/19420862.2019.1622940","article-title":"Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice","volume":"11","author":"Lombana","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.hlife.2026.03.004_bib60","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.3929380","article-title":"Transfectomas provide novel chimeric antibodies","volume":"229","author":"Morrison","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: The basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.hlife.2026.03.004_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2275598","article-title":"An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV","volume":"12","author":"Guo","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.hlife.2026.03.004_bib63","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc\u03b3RI, Fc\u03b3RII, Fc\u03b3RIII, and FcRn and design of IgG1 variants with improved binding to the Fc\u03b3R","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hlife.2026.03.004_bib64","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hlife.2026.03.004_bib65","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences","volume":"169","author":"Dall'Acqua","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","article-title":"Optimization of Fc-mediated effector functions of monoclonal antibodies","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.hlife.2026.03.004_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13238-017-0433-3","article-title":"Glycosylation engineering of therapeutic IgG antibodies: Challenges for the safety, functionality and efficacy","volume":"9","author":"Mimura","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib68","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: Recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.hlife.2026.03.004_bib69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40259-025-00720-6","article-title":"Understanding IgM structure and biology to engineer new antibody therapeutics","volume":"39","author":"Buchner","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.hlife.2026.03.004_bib70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrd2804","article-title":"Glycosylation as a strategy to improve antibody-based therapeutics","volume":"8","author":"Jefferis","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.03.004_bib72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib73","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s13361-016-1378-0","article-title":"Site-specific N-glycosylation of recombinant pentameric and hexameric human IgM","volume":"27","author":"Moh","year":"2016","journal-title":"J Am Soc Mass Spectrom"},{"key":"10.1016\/j.hlife.2026.03.004_bib74","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.4049\/jimmunol.167.9.5185","article-title":"The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA","volume":"167","author":"Johansen","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib75","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10640","article-title":"The structure and dynamics of secretory component and its interactions with polymeric immunoglobulins","volume":"5","author":"Stadtmueller","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.hlife.2026.03.004_bib76","first-page":"161","article-title":"Lack of evidence for IgM-induced ADCC: Studies with monoclonal and polyclonal antibodies","volume":"43","author":"Rumpold","year":"1981","journal-title":"Immunology"},{"key":"10.1016\/j.hlife.2026.03.004_bib77","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0171-2985(81)80089-7","article-title":"Comparison between human IgM and IgG antibodies to dextran, regarding their activities in antibody-dependent cellular cytotoxicity (ADCC)","volume":"159","author":"Rumpold","year":"1981","journal-title":"Immunobiology"},{"key":"10.1016\/j.hlife.2026.03.004_bib78","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4049\/jimmunol.152.3.1206","article-title":"Mapping of amino acid residues in the Cmu3 domain of mouse IgM important in macromolecular assembly and complement-dependent cytolysis","volume":"152","author":"Arya","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib79","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/eji.1830170418","article-title":"Complement activation by IgM: Evidence for the importance of the third constant domain of the mu heavy chain","volume":"17","author":"Shulman","year":"1987","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.hlife.2026.03.004_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108716","article-title":"Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19","volume":"226","author":"Satyam","year":"2021","journal-title":"Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.hlife.2026.03.004_bib82","article-title":"The long elusive IgM Fc receptor, Fc\u03bcR","volume":"34","author":"Kubagawa","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib83","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2019.00529","article-title":"Role of the IgM Fc receptor in immunity and tolerance","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib84","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3389\/fimmu.2019.00945","article-title":"Functional Roles of the IgM Fc receptor in the immune system","volume":"10","author":"Kubagawa","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib85","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1172\/JCI104987","article-title":"Metabolism of human gamma macroglobulins","volume":"43","author":"Barth","year":"1964","journal-title":"J Clin Investig"},{"key":"10.1016\/j.hlife.2026.03.004_bib86","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41594-023-00985-x","article-title":"Structural basis for Fc receptor recognition of immunoglobulin M","volume":"30","author":"Chen","year":"2023","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2019.140266","article-title":"Mapping of the binding site for Fc\u03bcR in human IgM-Fc","volume":"1868","author":"Nyamboya","year":"2020","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"10.1016\/j.hlife.2026.03.004_bib88","first-page":"US10899835","article-title":"Inventors; IGM biosciences Inc., assignee. IgM Fc and J-chain mutations that affect IgM serum half-life","author":"Baliga","year":"2021","journal-title":"US patent"},{"key":"10.1016\/j.hlife.2026.03.004_bib89","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/v14081739","article-title":"Antibody-dependent enhancement: \u201cEvil\u201d antibodies favorable for viral infections","volume":"14","author":"Yang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.hlife.2026.03.004_bib90","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.cell.2021.06.021","article-title":"In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib91","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/jvi.57.3.952-959.1986","article-title":"Interaction of West Nile virus with primary murine macrophages: Role of cell activation and receptors for antibody and complement","volume":"57","author":"Cardosa","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.ai.2021.08.003","article-title":"Antibody dependent enhancement: Unavoidable problems in vaccine development","volume":"151","author":"Xu","year":"2021","journal-title":"Adv Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib93","series-title":"Dynamics of immune activation in viral diseases","first-page":"9","article-title":"Antibody-dependent enhancement of viral infections","author":"Kulkarni","year":"2020"},{"key":"10.1016\/j.hlife.2026.03.004_bib94","doi-asserted-by":"crossref","first-page":"29080","DOI":"10.1074\/jbc.M504528200","article-title":"Human serum IgM glycosylation: Identification of glycoforms that can bind to mannan-binding lectin","volume":"280","author":"Arnold","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hlife.2026.03.004_bib95","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/14712598.2015.1069271","article-title":"Using glyco-engineering to produce therapeutic proteins","volume":"15","author":"Dicker","year":"2015","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.hlife.2026.03.004_bib96","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1073\/pnas.1404904111","article-title":"Designed IgM from glycoengineering","volume":"111","author":"Hiatt","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1147960","article-title":"Glyco engineered pentameric SARS-CoV-2 IgMs show superior activities compared to IgG1 orthologues","volume":"14","author":"Kallolimath","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2022.925008","article-title":"Humanization and expression of IgG and IgM antibodies in plants as potential diagnostic reagents for Valley fever","volume":"13","author":"Jugler","year":"2022","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib99","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41467-023-44211-0","article-title":"IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition","volume":"15","author":"Haslund-Gourley","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib100","first-page":"387","article-title":"Effect of culture conditions on IgM antibody structure, pharmacokinetics and activity","volume":"11","author":"Maiorella","year":"1993","journal-title":"Technology"},{"key":"10.1016\/j.hlife.2026.03.004_bib101","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1073\/pnas.1320544111","article-title":"Expression and glycoengineering of functionally active heteromultimeric IgM in plants","volume":"111","author":"Loos","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib102","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3389\/fimmu.2018.02485","article-title":"Improving immunotherapy through glycodesign","volume":"9","author":"Buettner","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib103","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.str.2021.01.002","article-title":"Structure of the human secretory immunoglobulin M core","volume":"29","author":"Kumar","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.hlife.2026.03.004_bib104","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2019-131650","article-title":"High avidity IgM-based CD20xCD3 bispecific antibody (IGM-2323) for enhanced T-cell dependent killing with minimal cytokine release","volume":"134","author":"Baliga","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hlife.2026.03.004_bib105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-134983","article-title":"Preliminary results of a Phase 1 dose escalation study of the first-in-class igm based bispecific antibody IGM-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies","volume":"136","author":"Budde","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hlife.2026.03.004_bib106","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hlife.2026.03.004_bib108","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: Expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hlife.2026.03.004_bib109","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.hlife.2026.03.004_bib110","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody\u2013PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Ma","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib111","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202153956","article-title":"Potent neutralization by monoclonal human IgM against SARS-CoV-2 is impaired by class switch","volume":"23","author":"Callegari","year":"2022","journal-title":"EMBO Rep"},{"key":"10.1016\/j.hlife.2026.03.004_bib112","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1038\/s41467-025-59294-0","article-title":"An intranasally administered IgM protects against antigenically distinct subtypes of influenza A viruses","volume":"16","author":"Ramesh","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib113","article-title":"IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2","volume":"219","author":"Hale","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib114","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/651022","article-title":"Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus","volume":"201","author":"Rockx","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.hlife.2026.03.004_bib115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s44298-025-00119-8","article-title":"A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion glycoprotein","volume":"3","author":"Oraby","year":"2025","journal-title":"Npj Viruses"},{"key":"10.1016\/j.hlife.2026.03.004_bib116","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.hlife.2026.03.004_bib117","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMe2002387","article-title":"Covid-19 \u2014 Navigating the uncharted","volume":"382","author":"Fauci","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib118","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","article-title":"World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)","volume":"76","author":"Sohrabi","year":"2020","journal-title":"Int J Surg"},{"key":"10.1016\/j.hlife.2026.03.004_bib119","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib121","doi-asserted-by":"crossref","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib123","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib124","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.hlife.2026.03.004_bib125","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.03.004_bib126","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.hlife.2026.03.004_bib128","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.hlife.2024.02.001","article-title":"A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif","volume":"2","author":"Su","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.hlife.2026.03.004_bib129","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41467-022-33030-4","article-title":"IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern","volume":"13","author":"Chang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib130","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1038\/s41467-022-33284-y","article-title":"Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth","volume":"13","author":"Ku","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib131","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib132","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib133","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cmet.2019.08.005","article-title":"Partial leptin reduction as an insulin sensitization and weight loss strategy","volume":"30","author":"Zhao","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.hlife.2026.03.004_bib134","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41467-020-20789-7","article-title":"Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape","volume":"12","author":"Ku","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib135","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2212415","article-title":"Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2","volume":"15","author":"Verstraete","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.hlife.2026.03.004_bib136","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib137","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.hlife.2026.03.004_bib251","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1014071","article-title":"Neutralization of SARS-CoV-2 by IgM-14 via engagement of two distinct spike epitopes","volume":"22","author":"Wang","year":"2026","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.hlife.2026.03.004_bib138","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.03.004_bib139","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-022-04464-z","article-title":"ACE2 binding is an ancestral and evolvable trait of sarbecoviruses","volume":"603","author":"Starr","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.03.004_bib140","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","article-title":"Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2","volume":"24","author":"Li","year":"2005","journal-title":"EMBO J"},{"key":"10.1016\/j.hlife.2026.03.004_bib141","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.03.004_bib142","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1038\/s41467-025-60286-3","article-title":"ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses","volume":"16","author":"Catanzaro","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib143","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2025.01.042","article-title":"Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor","volume":"188","author":"Chen","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1738","article-title":"An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants","volume":"7","author":"Chan","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.hlife.2026.03.004_bib145","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00964-21","article-title":"The K18-human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus","volume":"96","author":"Dong","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib146","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq6527","article-title":"Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo","volume":"8","author":"Torchia","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.hlife.2026.03.004_bib147","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1038\/s41467-021-24013-y","article-title":"Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2","volume":"12","author":"Higuchi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib148","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib149","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.abc0870","article-title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","volume":"369","author":"Chan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib150","doi-asserted-by":"crossref","first-page":"28046","DOI":"10.1073\/pnas.2016093117","article-title":"Engineered ACE2 receptor traps potently neutralize SARS-CoV-2","volume":"117","author":"Glasgow","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib151","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41594-020-00549-3","article-title":"A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent","volume":"28","author":"Xiao","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib152","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01283-20","article-title":"SARS-CoV-2 and three related coronaviruses utilize multiple ACE2 orthologs and are potently blocked by an improved ACE2-Ig","volume":"94","author":"Li","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib153","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib154","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(20)30418-5","article-title":"Human recombinant soluble ACE2 in severe COVID-19","volume":"8","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib156","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-021-00821-y","article-title":"A binding-enhanced but enzymatic activity-eliminated human ACE2 efficiently neutralizes SARS-CoV-2 variants","volume":"7","author":"Zheng","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.hlife.2026.03.004_bib157","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.jmb.2017.06.015","article-title":"A perspective on the structural and functional constraints for immune evasion: Insights from influenza virus","volume":"429","author":"Wu","year":"2017","journal-title":"J Mol Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib158","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038778","article-title":"Influenza hemagglutinin structures and antibody recognition","volume":"10","author":"Wu","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib159","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a040964","article-title":"Influenza immunization in the context of preexisting immunity","volume":"11","author":"Linderman","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib160","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","article-title":"Influenza","volume":"400","author":"Uyeki","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.hlife.2026.03.004_bib161","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ni.3684","article-title":"Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins","volume":"18","author":"Nachbagauer","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib162","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009106","article-title":"New class of monoclonal antibodies against severe influenza: Prophylactic and therapeutic efficacy in ferrets","volume":"5","author":"Friesen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.hlife.2026.03.004_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1669073","article-title":"Monoclonal antibodies against influenza viruses: A clinical trials review","volume":"16","author":"Mota","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.hlife.2026.03.004_bib165","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib166","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib167","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib168","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1128\/JVI.01388-13","article-title":"Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site","volume":"87","author":"Hong","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib169","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2015.04.028","article-title":"Viral receptor-binding site antibodies with diverse germline origins","volume":"161","author":"Schmidt","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib170","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.1111497108","article-title":"Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin","volume":"108","author":"Whittle","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib171","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/prot.24745","article-title":"Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage","volume":"83","author":"Xu","year":"2015","journal-title":"Proteins"},{"key":"10.1016\/j.hlife.2026.03.004_bib172","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1073\/pnas.1715471115","article-title":"Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody","volume":"115","author":"Raymond","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib173","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/9299","article-title":"A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site","volume":"6","author":"Fleury","year":"1999","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib174","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1128\/JVI.00420-14","article-title":"Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses","volume":"88","author":"Iba","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib175","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01035-19","article-title":"Mapping of a novel H3-specific broadly neutralizing monoclonal antibody targeting the hemagglutinin globular head isolated from an elite influenza virus-immunized donor exhibiting serological breadth","volume":"94","author":"Qiu","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000350","article-title":"Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses","volume":"5","author":"Yoshida","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.hlife.2026.03.004_bib177","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.immuni.2017.12.009","article-title":"Memory B cells that cross-react with group 1 and group 2 influenza A viruses are abundant in adult human repertoires","volume":"48","author":"McCarthy","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.hlife.2026.03.004_bib178","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","article-title":"A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface","volume":"177","author":"Bangaru","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.hlife.2026.03.004_bib179","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1128\/JVI.05397-11","article-title":"Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5","volume":"85","author":"Ohshima","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/1744666X.4.4.497","article-title":"Innate immunity to influenza virus: Implications for future therapy","volume":"4","author":"White","year":"2008","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib181","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.1016\/j.vaccine.2012.09.082","article-title":"Distribution of surface glycoproteins on influenza A virus determined by electron cryotomography","volume":"30","author":"Wasilewski","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.hlife.2026.03.004_bib182","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.158.3803.933","article-title":"Ultrastructure of gamma M immunoglobulin and alpha macroglobulin: Electron-microscopic study","volume":"158","author":"Svehag","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.03.004_bib183","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(23)00393-6","article-title":"Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: A randomised, double-blind, dose-ascending, placebo-controlled, Phase 1\/2 trial","volume":"24","author":"Maranda","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.hlife.2026.03.004_bib184","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s43556-020-00014-z","article-title":"Developing inhaled protein therapeutics for lung diseases","volume":"1","author":"Matthews","year":"2020","journal-title":"Mol Biomed"},{"key":"10.1016\/j.hlife.2026.03.004_bib185","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/17425247.2015.999039","article-title":"Nebulization as a delivery method for mAbs in respiratory diseases","volume":"12","author":"Respaud","year":"2015","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.hlife.2026.03.004_bib186","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.hlife.2026.03.004_bib187","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib188","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib189","article-title":"Recommendations for the prevention of RSV disease in infants and children: Policy statement","volume":"156","year":"2025","journal-title":"Pediatrics"},{"key":"10.1016\/j.hlife.2026.03.004_bib190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10409230802058320","article-title":"Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme","volume":"43","author":"White","year":"2008","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib191","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrmicro1326","article-title":"Virus membrane-fusion proteins: More than one way to make a hairpin","volume":"4","author":"Kielian","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.hlife.2026.03.004_bib192","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","article-title":"The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.hlife.2026.03.004_bib193","first-page":"93","article-title":"Acid-induced membrane fusion by the hemagglutinin protein and its role in influenza virus biology","volume":"385","author":"Russell","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib194","article-title":"A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of intranasal plus intraoral IGM-6268 in healthy volunteers","author":"Funke","year":"2021","journal-title":"ClinicalTrials"},{"key":"10.1016\/j.hlife.2026.03.004_bib195","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hlife.2026.03.004_bib196","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: Delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.03.004_bib247","article-title":"A Phase 1\/2 open-label, multicenter study evaluating the safety and pharmacokinetics of imvotamab (IGM-2323) as a single agent and in combination in subjects with relapsed\/refractory non-hodgkin lymphomas","year":"2019","journal-title":"ClinicalTrials"},{"key":"10.1016\/j.hlife.2026.03.004_bib244","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1538-7445.AM2024-1237","article-title":"Abstract 1237: IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma","volume":"84","author":"Hart","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.hlife.2026.03.004_bib248","article-title":"IGM Biosciences, Inc. An open-label, multicenter, Phase 1 study of IGM-2644 in participants with relapsed and\/or refractory multiple myeloma","author":"Manley","year":"2023","journal-title":"ClinicalTrials"},{"key":"10.1016\/j.hlife.2026.03.004_bib249","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1538-7445.AM2023-2959","article-title":"Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanisms","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.hlife.2026.03.004_bib250","article-title":"IGM Biosciences, Inc. An open-label, multicenter, Phase 1a\/1b Study of aplitibart (IGM-8444) as a single agent and in combination in participants with relapsed, refractory, or newly diagnosed cancers","author":"Humke","year":"2020","journal-title":"ClinicalTrials"},{"key":"10.1016\/j.hlife.2026.03.004_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168418","article-title":"The essential functions of molecular chaperones and folding enzymes in maintaining endoplasmic reticulum homeostasis","volume":"436","author":"Hendershot","year":"2024","journal-title":"J Mol Biol"},{"key":"10.1016\/j.hlife.2026.03.004_bib198","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1073\/pnas.0903036106","article-title":"Efficient IgM assembly and secretion require the plasma cell induced endoplasmic reticulum protein pERp1","volume":"106","author":"van Anken","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.03.004_bib199","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4161\/mabs.1.2.7945","article-title":"High level expression of functional human IgMs in human PER.C6 cells","volume":"1","author":"Tchoudakova","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.hlife.2026.03.004_bib200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4236\/abb.2013.44A006","article-title":"Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production","volume":"4","author":"Mader","year":"2013","journal-title":"Adv Biosci Biotechnol"},{"key":"10.1016\/j.hlife.2026.03.004_bib201","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10616-014-9693-4","article-title":"Evaluating the bottlenecks of recombinant IgM production in mammalian cells","volume":"67","author":"Chromikova","year":"2015","journal-title":"Cytotechnology"},{"key":"10.1016\/j.hlife.2026.03.004_bib202","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/emboj\/21.4.835","article-title":"ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family","volume":"21","author":"Anelli","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.hlife.2026.03.004_bib203","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.3390\/ijms26157189","article-title":"Recent advances in engineering the unfolded protein response in recombinant Chinese hamster ovary cell lines","volume":"26","author":"Rives","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib204","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1600-0854.2010.01043.x","article-title":"ERp44 and ERGIC-53 synergize in coupling efficiency and fidelity of IgM polymerization and secretion","volume":"11","author":"Cortini","year":"2010","journal-title":"Traffic"},{"key":"10.1016\/j.hlife.2026.03.004_bib205","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/21645515.2016.1260795","article-title":"Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules","volume":"13","author":"Legastelois","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.hlife.2026.03.004_bib206","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3038564","article-title":"Plant-produced monoclonal antibody as immunotherapy for cancer","volume":"2020","author":"Nessa","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.hlife.2026.03.004_bib207","doi-asserted-by":"crossref","first-page":"15923","DOI":"10.1074\/jbc.M109.088401","article-title":"In planta protein sialylation through overexpression of the respective mammalian pathway","volume":"285","author":"Castilho","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hlife.2026.03.004_bib208","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4161\/mabs.1.2.7945","article-title":"High level expression of functional human IgMs in human PER.C6\u00ae cells","volume":"1","author":"Tchoudakova","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.hlife.2026.03.004_bib209","series-title":"CaptureSelect\u00ae affinity products","year":"2026"},{"key":"10.1016\/j.hlife.2026.03.004_bib210","first-page":"40","article-title":"IgM purification with hydroxyapatite","volume":"12","author":"Gagnon","year":"2014","journal-title":"Bioprocess Int"},{"key":"10.1016\/j.hlife.2026.03.004_bib211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chroma.2011.10.034","article-title":"Technology trends in antibody purification","volume":"1221","author":"Gagnon","year":"2012","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.hlife.2026.03.004_bib212","first-page":"26","article-title":"Purification of IgM monoclonal antibodies","volume":"2008","author":"Gagnon","year":"2008","journal-title":"BioPharm Int Sup"},{"key":"10.1016\/j.hlife.2026.03.004_bib213","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.biotechadv.2011.07.001","article-title":"Immunoglobulin-M purification \u2014 Challenges and perspectives","volume":"29","author":"Gautam","year":"2011","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.hlife.2026.03.004_bib214","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/chromatography2020195","article-title":"Monoliths in bioprocess technology","volume":"2","author":"Rajamanickam","year":"2015","journal-title":"Chromatography"},{"key":"10.1016\/j.hlife.2026.03.004_bib215","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/biot.201200328","article-title":"Functional monolithic platforms: Chromatographic tools for antibody purification","volume":"8","author":"Barroso","year":"2013","journal-title":"Biotechnol J"},{"key":"10.1016\/j.hlife.2026.03.004_bib216","first-page":"30","article-title":"Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal","volume":"6","author":"Waller","year":"2023","journal-title":"Antib Ther"},{"key":"10.1016\/j.hlife.2026.03.004_bib217","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hlife.2026.03.004_bib218","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1529\/biophysj.104.047746","article-title":"The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation","volume":"87","author":"Armstrong","year":"2004","journal-title":"Biophys J"},{"key":"10.1016\/j.hlife.2026.03.004_bib219","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: Opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Deliv Transl Res"},{"key":"10.1016\/j.hlife.2026.03.004_bib220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/19420862.2015.1128606","article-title":"Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development","volume":"8","author":"Tomar","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.hlife.2026.03.004_bib221","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1021\/acs.molpharmaceut.1c00561","article-title":"New model to predict the concentration-dependent viscosity of monoclonal antibody solutions","volume":"18","author":"Dandekar","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.hlife.2026.03.004_bib222","first-page":"284","article-title":"Inhalable and nasal biologics: Analytical, formulation, development, and regulatory considerations","volume":"38","author":"Cipolla","year":"2025","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.hlife.2026.03.004_bib223","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1038\/s41467-023-40933-3","article-title":"An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlife.2026.03.004_bib224","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2273.1999.00223.x","article-title":"Nasal pH measurement: A reliable and repeatable parameter","volume":"24","author":"England","year":"1999","journal-title":"Clin Otolaryngol Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1023\/A:1015830907632","article-title":"The Nasal mucociliary clearance: Relevance to nasal drug delivery","volume":"8","author":"Schipper","year":"1991","journal-title":"Pharm Res"},{"key":"10.1016\/j.hlife.2026.03.004_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124472","article-title":"Histidine as a versatile excipient in the protein-based biopharmaceutical formulations","volume":"662","author":"Lv","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.hlife.2026.03.004_bib227","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/jps.21190","article-title":"Polysorbates 20 and 80 used in the Formulation of protein biotherapeutics: Structure and degradation pathways","volume":"97","author":"Kerwin","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib228","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jps.20364","article-title":"Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction, and\/or immobilization in a glassy matrix?","volume":"94","author":"Chang","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib229","article-title":"Optimization of a novel expression system for recombinant protein production in CHO cells","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlife.2026.03.004_bib230","doi-asserted-by":"crossref","first-page":"P14","DOI":"10.1186\/1753-6561-9-S9-P14","article-title":"Novel cell engineering of the unfolded protein response to achieve efficient therapeutic protein production cell line","volume":"9","author":"Song","year":"2015","journal-title":"BMC Proc"},{"key":"10.1016\/j.hlife.2026.03.004_bib231","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.03.004_bib232","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: A review of volunteer challenge studies","volume":"167","author":"Carrat","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.hlife.2026.03.004_bib233","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1164\/rccm.201002-0221OC","article-title":"Viral load drives disease in humans experimentally infected with respiratory syncytial virus","volume":"182","author":"DeVincenzo","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib234","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s15010-023-02125-5","article-title":"Early combination therapy of COVID-19 in high-risk patients","volume":"52","author":"Orth","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.hlife.2026.03.004_bib235","article-title":"B-cell-depleted patients with persistent SARS-CoV-2 infection: Combination therapy or monotherapy? A real-world experience","volume":"11","author":"D'Abramo","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.hlife.2026.03.004_bib236","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hlife.2026.03.004_bib237","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: Development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.03.004_bib238","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.tips.2022.12.005","article-title":"Computational and artificial intelligence-based methods for antibody development","volume":"44","author":"Kim","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.hlife.2026.03.004_bib239","doi-asserted-by":"crossref","first-page":"W159","DOI":"10.1093\/nar\/gkae420","article-title":"AggreProt: A web server for predicting and engineering aggregation prone regions in proteins","volume":"52","author":"Planas-Iglesias","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.hlife.2026.03.004_bib240","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt5111","article-title":"Massive experimental quantification allows interpretable deep learning of protein aggregation","volume":"11","author":"Thompson","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.hlife.2026.03.004_bib241","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/vaccines11101585","article-title":"Next generation mucosal vaccine strategy for respiratory pathogens","volume":"11","author":"Dotiwala","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.hlife.2026.03.004_bib242","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/1538-7445.AM2024-1899","article-title":"Abstract 1899: Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models","volume":"84","author":"Desbois","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.hlife.2026.03.004_bib243","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/01.HS9.0000847968.95263.25","article-title":"P1276: Dose response profile of IGM-2323, a CD20xCD3 igm bispecific T cell engager, in translational models supports Phase 2 dose selection in non-hodgkin\u2019s lymphoma","volume":"6","author":"Leabman","year":"2022","journal-title":"HemaSphere"},{"issue":"Suppl 2","key":"10.1016\/j.hlife.2026.03.004_bib245","article-title":"711 IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion","volume":"9","author":"Giffon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hlife.2026.03.004_bib246","series-title":"IGM Biosciences provides strategic update on autoimmunity pipeline programs","year":"2025"}],"container-title":["hLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949928326000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949928326000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:45:04Z","timestamp":1783169104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949928326000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":250,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2949928326000180"],"URL":"https:\/\/doi.org\/10.1016\/j.hlife.2026.03.004","relation":{},"ISSN":["2949-9283"],"issn-type":[{"value":"2949-9283","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering nasally delivered IgM antibodies for respiratory viral infections","name":"articletitle","label":"Article Title"},{"value":"hLife","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlife.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Institute of Microbiology, Chinese Academy of Sciences.","name":"copyright","label":"Copyright"}]}}